ArriVent Biopharma paid $47m to license MRG007, a Phase 1-ready gastrointestinal cancer therapy developed by Shanghai’s Lepu Biopharma. The antibody drug conjugate has not had its target disclosed but ArriVent said studies showed it had “best-in-class potential”, and suggested it could be a drug that targets claudin 18.2. ArriVent said MRG007 displayed strong anti-tumour action in preclinical models, with the first submissions expected in H1 2022.
Nearly 700,000 customers impacted after insider attack at US fintech firm
FinWise, which provides loans on behalf of US financial services firms, revealed a former employee accessed sensitive customer information after leaving the firm.
